Pharmaceutical

invIOs’s cell therapy secures Austrian Government grant for Phase Ib trial

Up to 45% of the trial costs for the dose-determining Phase 1b trial will be funded by the Austrian research promotion agency.

Sep 5, 2023 - 20:00
invIOs’s cell therapy secures Austrian Government grant for Phase Ib trial
Up to 45% of the trial costs for the dose-determining Phase 1b trial will be funded by the Austrian research promotion agency.
Read the original article

Tags:

Previous Article

VTE risk elevated in Swedish patients hospitalised for Covid-19

Next Article

Cipla to bolster OTC portfolio with acquisition of Actor Pharma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Diakonos’ brain tumour vaccine wins FDA’s orphan drug designation

Diakonos’ brain tumour vaccine wins FDA’s orphan drug d...

Jan 3, 2024

Avadel Pharmaceuticals gets grant for patent granted for modified release formulation of gamma-hydroxybutyrate

Avadel Pharmaceuticals gets grant for patent granted fo...

Jun 8, 2024

STAT+: Biden administration asks judge to toss out Humana’s Medicare Advantage audit lawsuit

STAT+: Biden administration asks judge to toss out Huma...

Dec 19, 2023